Practice
Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus
Nicola Goldberg and Michael Fralick
CMAJ May 23, 2017 189 (20) E724; DOI: https://doi.org/10.1503/cmaj.161455
Nicola Goldberg
Department of Medicine (Goldberg), University of Toronto, Toronto, Ont.; Division of Pharmacoepidemiology and Pharmacoeconomics (Fralick), Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass.; Division of General Internal Medicine (Fralick), Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ont.
MD MPAMichael Fralick
Department of Medicine (Goldberg), University of Toronto, Toronto, Ont.; Division of Pharmacoepidemiology and Pharmacoeconomics (Fralick), Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass.; Division of General Internal Medicine (Fralick), Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ont.
MDRelated Articles
- No related articles found.
In this issue
Article tools
Respond to this article
Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus
Nicola Goldberg, Michael Fralick
CMAJ May 2017, 189 (20) E724; DOI: 10.1503/cmaj.161455
Jump to section
- Article
- Sodium–glucose cotransporter 2 inhibitors are a new class of oral drugs for treating diabetes
- Sodium–glucose cotransporter 2 inhibitors may reduce mortality in patients with type 2 diabetes at high risk for cardiovascular events
- Sodium–glucose cotransporter 2 inhibitors have a unique adverse-effect profile
- Sodium–glucose cotransporter 2 inhibitors should be used with caution in patients on insulin, insulin secretagogues and diuretics
- Empagliflozin, dapagliflozin and canagliflozin are available in Canada
- Footnotes
- References
- Responses
- Metrics
Related Articles
- No related articles found.
Cited By...
- No citing articles found.